The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
about
Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicabilityMeasures of disability: Arthritis Impact Measurement Scales 2 (AIMS2), Arthritis Impact Measurement Scales 2-Short Form (AIMS2-SF), The Organization for Economic Cooperation and Development (OECD) Long-Term Disability (LTD) Questionnaire, EQ-5D, WorComparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular ViewAdalimumab for the treatment of rheumatoid arthritisIncorporating data from various trial designs into a mixed treatment comparison model.Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.Comparative effectiveness research with administrative health data in rheumatoid arthritis.Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational studySeven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity.Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritisLow infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study.Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritisThe comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare populationThe role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agentsLong-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers.When is switching warranted among biologic therapies in rheumatoid arthritis?Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.Adalimumab in the treatment of rheumatoid arthritis.Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review.Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?Selected cytokine pathways in rheumatoid arthritis.Patients' preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists.Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists.Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis.Evaluation of Anti-inflammatory Effects of Steroids and Arthritis-Related Biotherapies in an In Vitro Coculture Model with Immune Cells and Synoviocytes.Circulating Biomarkers for Predicting Infliximab Response in Rheumatoid Arthritis: A Systematic Bioinformatics Analysis.The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register).Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience.Dual energy CT iodine map for delineating inflammation of inflammatory arthritis.Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs.Improved safety of biologic therapy for rheumatoid arthritis over the 8-year period since implementation in Japan: long-term results from a multicenter observational cohort study.Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database.DNA methylation as a marker of response in rheumatoid arthritis.Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis.
P2860
Q26771652-B8D42275-CB8B-4017-A282-2CB8880F47B4Q26829085-9FF8047B-D95F-47E1-8D36-777F390DF923Q27679553-A0B8CE8E-0068-4097-A116-B32829A6FEE6Q28282655-29851EFE-5CE5-4226-9B88-912EBEE18327Q30594247-8ECCDEBD-80A5-421D-B7F8-9824B0DFE6A6Q30841797-044B55A0-8AB3-4EDF-879F-D49AF22A42E0Q31077662-48A2577F-654A-49BD-A09F-90387DA08E2BQ33984823-7006A66B-D4FF-4754-842F-20B58F77BD8AQ34027422-C75E73DA-75FD-423C-A040-DFE7743C56C2Q34211769-4B1128A6-5CAC-4AEB-885E-6E523ECE4822Q34420269-631DD18D-9BB4-4CB7-BF0A-A065E1C4EB40Q34462584-83282D49-F848-439C-B45D-5051B3259B51Q35048347-9ECDA8CC-58FC-450C-8891-B94A07A4D7C9Q35581451-F1BC747F-3FAC-4432-BB9C-484EDF1DDCDEQ36410046-41B653B9-5C7E-41A5-B8FD-DF2C013220DFQ37301134-A6331C19-8419-44D9-9223-014DAE63F6EDQ37338261-8B163CF2-0C52-4697-BAB6-A6841C04DB37Q38027571-C170BFB8-6ADC-4A54-A254-CDFE52F3168DQ38034134-A7659CCD-0E59-4328-871E-3D1E62081972Q38192659-700422B4-5186-4D50-8EDE-3604BC1B973FQ38338700-CC7E300D-BCE6-4B1A-936A-830109C1606FQ38424589-229404A4-303A-437B-903D-DAFA7A7F08C8Q38598776-5C155846-1AC9-4AE1-8DCA-BBB8D9E2B64EQ38755912-09DEAD0B-6595-4F8B-92F7-3794A19BD6A9Q40405513-B1A69E6C-C9C9-405D-97B1-84E912CC118CQ40749335-90200A0B-3EA5-4181-A653-48BA67F2BC8EQ40787850-0209AC92-E128-496F-B817-CB9E62F880F0Q41908486-FCD32DF2-4A19-4139-9F72-D997B0A688CEQ42290532-A95332AB-1571-49D1-B19E-100F7569A604Q43194443-5BD95E2E-638D-48AF-82A3-1F580D91C700Q44020347-469B294D-DBEF-4CAC-B410-12A860D40D32Q47810854-0685899B-E8D7-4618-9411-5A02ABEC50CEQ47917968-9568F9F9-1604-4A49-A2CE-EE8D0B6F0B7BQ48058494-FD42486D-9521-496A-BCAC-134E79547599Q48253106-8DFEB5D0-7B14-47A5-BEA3-E15B9B5DC6EAQ50262782-2DC27B12-4B7F-4BE0-8EF8-E6CCEAF8C1F7Q51650310-5DC102D8-CA97-40F6-88F9-60CC947F1E0DQ52536411-46BB7FC2-E440-4762-85C9-B1EE60343E5FQ53123281-A40BD7D4-98AC-4757-A1E4-63D1C5C4B696
P2860
The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The effectiveness and medicati ...... ective clinical practice data.
@ast
The effectiveness and medicati ...... ective clinical practice data.
@en
type
label
The effectiveness and medicati ...... ective clinical practice data.
@ast
The effectiveness and medicati ...... ective clinical practice data.
@en
prefLabel
The effectiveness and medicati ...... ective clinical practice data.
@ast
The effectiveness and medicati ...... ective clinical practice data.
@en
P2093
P356
P1476
The effectiveness and medicati ...... ective clinical practice data.
@en
P2093
C M A De Gendt
D-J R A M De Rooij
H L M Brus
M A F J van de Laar
P C L M Van Riel
P C M Van Oijen
T L Jansen
P304
P356
10.1136/ARD.2007.083675
P407
P577
2008-01-03T00:00:00Z